{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:28:24Z","timestamp":1788193704968,"version":"build-2803163510"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018635","name":"Thousand Young Talents Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["WF220408211"],"award-info":[{"award-number":["WF220408211"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2017MS18"],"award-info":[{"award-number":["YG2017MS18"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.addr.2022.114525","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T05:15:48Z","timestamp":1662873348000},"page":"114525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers"],"prefix":"10.1016","volume":"190","author":[{"given":"Juanjuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingshun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinam","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114525_b0005","first-page":"467","article-title":"Targeted therapy using nanotechnology: focus on cancer","volume":"9","author":"Sanna","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114525_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2016.12.010","article-title":"The drug delivery field needs a well-diversified technology portfolio","volume":"245","author":"Park","year":"2017","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0020","first-page":"1","article-title":"Engineering precision nanoparticles for drug delivery","volume":"4","author":"Mitchell","year":"2020","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.addr.2022.114525_b0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114525_b0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-14-1882","article-title":"Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression","volume":"21","author":"Kang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.addr.2022.114525_b0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2019.05.044","article-title":"The beginning of the end of the nanomedicine hype","volume":"305","author":"Park","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jconrel.2019.08.016","article-title":"NCI Centers of Cancer Nanotechnology Excellence (CCNEs) \u2013 A full story to set the record straight","volume":"309","author":"Grodzinski","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0050","first-page":"271","article-title":"Polymeric nanoparticles: the future of nanomedicine","volume":"8","author":"Banik","year":"2016","journal-title":"Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2022.114525_b0055","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114525_b0060","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.addr.2022.114525_b0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0923-2516(07)80031-8","article-title":"Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation","volume":"145","author":"St\u00fcrzl","year":"1994","journal-title":"Res. Virol."},{"key":"10.1016\/j.addr.2022.114525_b0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2022.114525_b0075","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0080","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0085","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2165\/0003495-200868170-00008","article-title":"Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma","volume":"68","author":"Plosker","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2022.114525_b0090","first-page":"277","article-title":"Liposomal daunorubicin as treatment for Kaposi's sarcoma","volume":"2","author":"Petre","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114525_b0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/08982109409037058","article-title":"Daunoxome\u00ae Treatment of Solid Tumors: Preclinical and Clinical Investigations","volume":"4","author":"Forssen","year":"1994","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2022.114525_b0100","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/456409","article-title":"Liposomal Doxorubicin in the treatment of breast cancer patients: a review","volume":"2013","author":"Lao","year":"2013","journal-title":"J. Drug Delivery"},{"key":"10.1016\/j.addr.2022.114525_b0110","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","article-title":"Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer","volume":"23","author":"Ibrahim","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0115","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0120","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0125","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114525_b0130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","author":"Rajeshkumar","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0135","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrneph.2016.156","article-title":"Nanomedicines for renal disease: current status and future applications","volume":"12","author":"Kamaly","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2022.114525_b0140","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical Translation of Nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2022.114525_b0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.addr.2022.114525_b0150","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0160","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2013a report from the Children's Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamurtide for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"Ando","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.addr.2022.114525_b0175","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114525_b0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2015.10.048","article-title":"Drug delivery of the future: Chasing the invisible gorilla","volume":"240","author":"Park","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2017.07.021","article-title":"Watching the gorilla and questioning delivery dogma","volume":"262","author":"Anchordoquy","year":"2017","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2014.07.046","article-title":"Translation from mouse to human: time to think in new boxes","volume":"189","author":"Park","year":"2014","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0195","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2022.114525_b0200","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114525_b0205","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.xphs.2017.06.019","article-title":"Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection","volume":"106","author":"Natfji","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114525_b0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2013.06.039","article-title":"Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery","volume":"172","author":"Hollis","year":"2013","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0215","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"Evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0220","doi-asserted-by":"crossref","first-page":"12281","DOI":"10.1021\/acsnano.9b09713","article-title":"What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114525_b0225","doi-asserted-by":"crossref","first-page":"13620","DOI":"10.1021\/acsnano.9b08659","article-title":"Nanomedicines Lost in Translation","volume":"13","author":"Guidolin","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114525_b0230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2013.09.026","article-title":"Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice","volume":"172","author":"Stirland","year":"2013","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0235","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-020-01033-x","article-title":"Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials","volume":"123","author":"Atkins","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0240","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.nano.2014.04.011","article-title":"Just so stories: The random acts of anti-cancer nanomedicine performance","volume":"10","author":"Moghimi","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2022.114525_b0245","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-15-1558","article-title":"Recommendations for benchmarking preclinical studies of nanomedicines","volume":"75","author":"Dawidczyk","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2019.11.012","article-title":"Nanomedicine researchers: Slow down to speed up","volume":"315","author":"Allen","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0255","article-title":"How to do things with theory: The instrumental role of auxiliary hypotheses in testing","author":"Dethier","year":"2019","journal-title":"Erkenn."},{"key":"10.1016\/j.addr.2022.114525_b0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3758\/s13423-018-1488-8","article-title":"How to never be wrong","volume":"26","author":"Gershman","year":"2019","journal-title":"Bull. Psychon. Soc."},{"key":"10.1016\/j.addr.2022.114525_b0265","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.addr.2022.114525_b0270","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.addr.2022.114525_b0275","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0280","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","article-title":"Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin","volume":"20","author":"Seymour","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0285","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/bjc.1986.141","article-title":"Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug","volume":"53","author":"Cummings","year":"1986","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.addr.2022.114525_b0290","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-20-0008","article-title":"Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors","volume":"26","author":"Atrafi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.addr.2022.114525_b0295","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.3390\/cancers13153741","article-title":"Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634","volume":"13","author":"Atrafi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.addr.2022.114525_b0300","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1995.13.4.914","article-title":"Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma","volume":"13","author":"Harrison","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0305","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kope\u010dek","year":"2010","journal-title":"Advanced drug delivery reviews"},{"key":"10.1016\/j.addr.2022.114525_b0310","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.addr.2009.12.005","article-title":"Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities","volume":"62","author":"Duncan","year":"2010","journal-title":"Advanced drug delivery reviews"},{"key":"10.1016\/j.addr.2022.114525_b0315","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00124-2","article-title":"Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine","volume":"57","author":"Julyan","year":"1999","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0320","doi-asserted-by":"crossref","unstructured":"R.H. Blum, & S.K. Carter, Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. 80 (1974) 249-259.","DOI":"10.7326\/0003-4819-80-2-249"},{"key":"10.1016\/j.addr.2022.114525_b0325","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3892\/ijo_00000293","article-title":"Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer","volume":"34","author":"Seymour","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0330","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"Journal of controlled release"},{"issue":"46","key":"10.1016\/j.addr.2022.114525_b0335","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013169","article-title":"Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.addr.2022.114525_b0340","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41598-019-57380-0","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis","volume":"10","author":"Lee","year":"2020","journal-title":"Scientif Report"},{"key":"10.1016\/j.addr.2022.114525_b0345","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0350","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0355","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0360","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0365","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0370","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"Fridrik","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0380","first-page":"3961","article-title":"First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"28","author":"Jehn","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1359-6349(09)71801-4","article-title":"9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis","volume":"7","author":"Kosmas","year":"2009","journal-title":"EJC Suppl."},{"key":"10.1016\/j.addr.2022.114525_b0390","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2009.06.017","article-title":"Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB\/IV) non-small cell lung cancer","volume":"68","author":"Mylonakis","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0395","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/annonc\/mdq234","article-title":"Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial","volume":"21","author":"Stathopoulos","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0400","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0405","first-page":"208","article-title":"A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer","volume":"15","author":"Yang","year":"2012","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.addr.2022.114525_b0410","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mdu025","article-title":"A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)","volume":"25","author":"Awada","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1743-7563.2009.01235.x","article-title":"Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer","volume":"5","author":"Guan","year":"2009","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0420","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"Rugo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0425","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0430","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2022.114525_b0435","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2\/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0440","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4143\/crt.2016.289","article-title":"An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.addr.2022.114525_b0445","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0450","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0455","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114525_b0460","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","article-title":"Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis","volume":"7","author":"Johnson","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0465","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0470","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/028418600430789","article-title":"High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas\u2013rationale for combination with radiotherapy","volume":"39","author":"Koukourakis","year":"2000","journal-title":"Acta Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0480","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2012.44","article-title":"First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial","volume":"106","author":"Arrieta","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0485","first-page":"3031","article-title":"Systemic Lipoplatin infusion results in preferential tumor uptake in human studies","volume":"25","author":"Boulikas","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-008-0738-2","article-title":"Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study","volume":"63","author":"Pires","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2022.114525_b0495","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114525_b0500","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.addr.2022.114525_b0505","first-page":"589","article-title":"Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study","volume":"13","author":"Stathopoulos","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2022.114525_b0510","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/gyno.2002.6654","article-title":"Uptake of a cholesterol-rich emulsion by breast cancer","volume":"85","author":"Graziani","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0515","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/gyno.2001.6203","article-title":"Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues","volume":"82","author":"Ades","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0520","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00280-003-0685-x","article-title":"Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma","volume":"52","author":"Sarapa","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2022.114525_b0525","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","article-title":"A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0530","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.toxrep.2015.02.011","article-title":"Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.addr.2022.114525_b0535","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/bcp.14032","article-title":"Why maximum tolerated dose?","volume":"85","author":"Stampfer","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2022.114525_b0540","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0545","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0550","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0555","unstructured":"Doxorubicin Application in NCI, https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/doxorubicinhydrochloride , 2007."},{"key":"10.1016\/j.addr.2022.114525_b0560","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/mi.5.3.6","article-title":"The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine","volume":"5","author":"Peng","year":"2005","journal-title":"Mol. Interventions"},{"key":"10.1016\/j.addr.2022.114525_b0565","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.addr.2022.114525_b0570","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2022.114525_b0575","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0580","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/0277-5379(89)90350-7","article-title":"Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study","volume":"25","author":"Gabizon","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0585","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.1991.476","article-title":"Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin","volume":"64","author":"Gabizon","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/cgt.2017.9","article-title":"The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials","volume":"24","author":"Ansari","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.addr.2022.114525_b0595","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/GMIT.GMIT_8_17","article-title":"Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia","volume":"7","author":"Moreira-Barros","year":"2018","journal-title":"Gynecol. Minim. Invasive Ther."},{"key":"10.1016\/j.addr.2022.114525_b0600","doi-asserted-by":"crossref","unstructured":"Pharmacokinetics of Pegylated Liposomal Doxorubicin Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubici. Clinical pharmacokinetics, 42(5) (2003) 419-436.","DOI":"10.2165\/00003088-200342050-00002"},{"key":"10.1016\/j.addr.2022.114525_b0605","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","volume":"27","author":"Sparano","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0610","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.biopha.2017.09.059","article-title":"A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer","volume":"95","author":"Shafei","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2022.114525_b0615","unstructured":"FDA approves Abraxane for metastatic breast cancer, https:\/\/www.drugs.com\/newdrugs\/abraxane-american-pharmaceutical-partners-inc-american-bioscience-inc-metastatic-breast-cancer-143.html, 2005."},{"key":"10.1016\/j.addr.2022.114525_b0620","unstructured":"The European public assessment report (EPAR) for Abraxane, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abraxane, 2008."},{"key":"10.1016\/j.addr.2022.114525_b0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0630","unstructured":"The success story of Taxol development from NCI website, https:\/\/dtp.cancer.gov\/timeline\/flash\/success_stories\/S2_taxol.htm."},{"key":"10.1016\/j.addr.2022.114525_b0635","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","article-title":"The battle of \u201cnano\u201d paclitaxel","volume":"122","author":"Sofias","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.addr.2022.114525_b0640","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/OTT.S13836","article-title":"Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval","volume":"4","author":"Yamamoto","year":"2011","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.addr.2022.114525_b0645","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: a next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.addr.2022.114525_b0650","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-13-1356","article-title":"The winning formulation: the development of paclitaxel in pancreatic cancer","volume":"19","author":"Ma","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0655","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CEOR.S82194","article-title":"Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective","volume":"7","author":"Dranitsaris","year":"2015","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.addr.2022.114525_b0660","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0665","first-page":"753","article-title":"Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society","volume":"5","author":"Hartung","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0670","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-06-2776","article-title":"Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin","volume":"13","author":"Unger","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0675","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0680","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1756283X17705328","article-title":"Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer","volume":"10","author":"Rahman","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.addr.2022.114525_b0685","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","article-title":"Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2022.114525_b0690","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114525_b0695","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0700","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer-drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"Suppl","key":"10.1016\/j.addr.2022.114525_b0705","first-page":"S41","article-title":"Phase III studies of toremifene in metastatic breast cancer","volume":"16","author":"Pyrh\u00f6nen","year":"1990","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.addr.2022.114525_b0710","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2022.114525_b0715","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114525_b0720","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0725","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.7150\/jca.31130","article-title":"Glutathione S-transferases genes variants and chemotherapy efficacy in gastrointestinal cancer patients: a meta-analysis based on 50 pharmacogenetic studies","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.addr.2022.114525_b0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2020.10.015","article-title":"Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment","volume":"39","author":"Wheeler","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2022.114525_b0735","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114525_b0740","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/01926230252824798","article-title":"Quantitation of molecular endpoints for the dose-response component of cancer risk assessment","volume":"30","author":"Preston","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2022.114525_b0745","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2018.01.009","article-title":"Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small","volume":"272","author":"Tyagi","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2022.114525_b0750","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006516","article-title":"Generation of effector memory T cell\u2013based mucosal and systemic immunity with pulmonary nanoparticle vaccination","volume":"5","author":"Li","year":"2013","journal-title":"Science translational medicine"},{"key":"10.1016\/j.addr.2022.114525_b0755","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5447","article-title":"Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells","volume":"7","author":"Huang","year":"2015","journal-title":"Science translational medicine"},{"key":"10.1016\/j.addr.2022.114525_b0760","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nature biomedical engineering"},{"key":"10.1016\/j.addr.2022.114525_b0765","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.2147\/IJN.S254774","article-title":"Past, present, and future of anticancer nanomedicine","volume":"15","author":"Kim","year":"2020","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.addr.2022.114525_b0770","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.addr.2022.114525_b0775","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Failure Rev."},{"key":"10.1016\/j.addr.2022.114525_b0780","first-page":"15","article-title":"Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity","volume":"25","author":"Herman","year":"1998","journal-title":"Semin. Oncol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2200415X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2200415X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:24:18Z","timestamp":1777515858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X2200415X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":156,"alternative-id":["S0169409X2200415X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114525","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114525"}}